Abstracts
Pilot study with Intercept treated buffy coat derived platelet concentrates
Presented at: 22nd Congress of the Society of French Transfusion Sanguine (SFTS) 2005, 6/27/05 - 6/30/05
Background: Platelet concentrates (PC) still have a significant risk of transmitting pathogens, mainly bacteria. Pathogen reduction technologies have been devised to reduce this risk to a minimum. Intercept® (Baxter-Cerus) is a PRT which combine the addition of amotosalen and ultraviolet light illumination. We report here a pilot study where Intercept treated PC were prepared and transfused to patients.
Methods. After removing BC (OptipressII, Baxter)from whole blood donations after centrifugation, by top&bottom method, five ABO identical BC were pooled in additive solution (Intersol® for Intercept and Composol® PS, Fresenius for routine) and separated by centrifugation. PCs were treated with Intercept according to manufacturer instructions.
Results:
|
|
Intercept |
Routine |
|
|
Patients (n) |
25 |
10 |
|
|
Tx. (n) |
188 |
90 |
|
|
Pre-tx plat count |
12,3±14.1 |
14,1±11.5 |
NS |
|
1 h CCI |
10,065 ± 9,394 |
8,028 ± 6,866 |
NS |
|
24 h CCI |
5,090 ± 6,892 |
7,959 ± 6,339 |
0.002 |
|
Hours next tx. |
70.9 ± 90 |
87.6 ± 53.8 |
NS |
|
Platelet yield |
3,69 |
4,21 |
<0.0005 |
|
Days of storage |
2,55 |
3,68 |
<0.0005 |
|
Reactions (%) |
1.6 |
2.2 |
NS |
Conclusion: BC derived PC treated with Intercept produced an immediate transfusion response similar to that observed with routine PC. The 24 h-CCI was lower although the interval between transfusions was not significantly shortened. We did not find a significant relationship between days of storage and 1-, and 24-hours CCI.
|
